Are there any differences in the pharmacokinetics of eculizumab in different patient populations?

Apr 3, 2025 ... Eculizumab (brand names Soliris, Bkemv, Epysqli) is used to treat paroxysmal nocturnal hemoglobinuria (PNH) in adults, and a rare chronic blood ... Eculizumab injection is used to treat a type of blood disease called paroxysmal nocturnal hemoglobinuria (PNH). Oct 8, 2020 ... This guide is an educational resource to help patients and their caregivers understand health insurance coverage of SOLIRIS® (eculizumab). Learn ... Apr 10, 2019 ... Eculizumab (Soliris®, Alexion Pharmaceuticals, Inc., Boston, MA, USA) ... Soliris (eculizumab) [prescribing information]. Boston, MA ... Feb 22, 2023 ... This study demonstrates that the majority of patients benefit from eculizumab when adhering to the indications as formulated in the Dutch PNH guideline. See full prescribing information for Soliris. Soliris™ (eculizumab),. Concentrated solution for intravenous infusion. Initial U.S. Approval: 2007. WARNING: ... Soliris 300 mg concentrate for solution for infusion. Active Ingredient: eculizumab. Company: Alexion Pharma UK Ltd. See contact details. Access to Eculizumab for patients with aHUS. NHS England published NICE guidance for the use of Eculizumab for treating in aHUS in January 2015. Mar 17, 2025 ... Soliris (eculizumab) and cost ... The cost of Soliris can vary based on several factors, including your insurance coverage. Drug savings programs ... Soliris was approved by the U.S. Food and Drug Administration in 2019 for the treatment of adults with NMOSD who are positive for anti-AQP4 antibodies. The ...